# The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions

> **NCT05218616** · PHASE1 · UNKNOWN · sponsor: **JLLC NatiVita** · enrollment: 22 (estimated)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Aviga, capsules 50 mg / Sutent®, capsules 50 mg
- **DRUG:** Sutent®, capsules 50 mg / Aviga, capsules 50 mg

## Key facts

- **NCT ID:** NCT05218616
- **Lead sponsor:** JLLC NatiVita
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-21
- **Primary completion:** 2022-03-03
- **Final completion:** 2022-05-03
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2022-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218616, "The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05218616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*